VA San Diego Healthcare System, San Diego, California, USA; Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
Int J Geriatr Psychiatry. 2011 Aug;26(8):869-75. doi: 10.1002/gps.2619. Epub 2010 Sep 27.
Generalized anxiety disorder (GAD) is a prevalent psychiatric condition in older adults with deleterious effects on health and cognition. Although selective serotonin reuptake inhibitor (SSRI) medications have some efficacy as acute treatments for geriatric GAD, incomplete response is the most common outcome of monotherapy. We therefore developed a novel sequential treatment strategy, using personalized, modular cognitive-behavioral therapy (mCBT) to augment SSRI medication.
In an open label pilot study (N = 10), subjects received a sequenced trial of 12 weeks of escitalopram followed by 16 weeks of escitalopram augmented with mCBT. We also examined the maintenance effects of mCBT over a 28-week follow-up period following drug discontinuation and termination of psychotherapy.
Results suggest that (1) adding mCBT to escitalopram significantly reduced anxiety symptoms and pathological worry, resulting in full remission for most patients and (2) some patients maintained response after all treatments were withdrawn.
Findings suggest that mCBT may be an effective augmentation strategy when added to SSRI medication and provide limited support for the long-term benefit of mCBT after discontinuation of pharmacotherapy.
广泛性焦虑障碍(GAD)是老年人中常见的精神疾病,对健康和认知有不良影响。尽管选择性 5-羟色胺再摄取抑制剂(SSRI)药物作为老年 GAD 的急性治疗具有一定疗效,但单一疗法最常见的结果是反应不完全。因此,我们开发了一种新的序贯治疗策略,使用个性化、模块化认知行为疗法(mCBT)来增强 SSRI 药物治疗。
在一项开放标签的初步研究(N=10)中,受试者接受了为期 12 周的依西酞普兰治疗,随后进行了为期 16 周的依西酞普兰联合 mCBT 治疗。我们还在药物停药和心理治疗结束后 28 周的随访期间,检查了 mCBT 的维持效果。
结果表明,(1)依西酞普兰联合 mCBT 可显著降低焦虑症状和病理性担忧,使大多数患者完全缓解,(2)部分患者在所有治疗停止后仍保持反应。
研究结果表明,mCBT 可能是 SSRI 药物治疗的有效增效策略,并为药物治疗停药后 mCBT 的长期获益提供了有限支持。